Payment overview · 2025
General Payments
$3,598.80
49 reported records · 16 companies
Healthcare provider profile · identity verified
Jaime Luis Silva, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BROWNSVILLE, TX · NPI 1689634883
Verified facts
What the public records show
CMS Open Payments records show Jaime Luis Silva, MD received $3,598.80 in general payments during 2025 across 49 reported records.
Penumbra, Inc. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Verquvo.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Verquvo by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 699 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $1,068.47 | 29.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $783.54 | 21.8% | 7 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$501.12 | 13.9% | 9 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $198.14 | 5.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $197.35 | 5.5% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $192.03 | 5.3% | 7 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $117.62 | 3.3% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $114.65 | 3.2% | 1 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $111.17 | 3.1% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $103.18 | 2.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $71.10 | 2.0% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $53.81 | 1.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $41.02 | 1.1% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $21.32 | 0.6% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.71 | 0.5% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $6.57 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,865.68 | 48 |
| Travel and Lodging | $733.12 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $1,068.47 | 2 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $292.07 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $197.35 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $192.03 | 7 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $149.85 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $117.62 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $114.65 | 1 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $111.17 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $103.18 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $71.10 | 2 | 2025 |
Source payment records
|
|||||
| AMVIA EDGE Normalized: amvia edge |
Device | BIOTRONIK INC. | $64.65 | 1 | 2025 |
Source payment records
|
|||||
| Acticor 7 VR-T DX Normalized: acticor 7 vr t dx |
Device | BIOTRONIK INC. | $64.65 | 1 | 2025 |
Source payment records
|
|||||
| Rivacor 7 DR-T Normalized: rivacor 7 dr t |
Device | BIOTRONIK INC. | $64.65 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $53.81 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $26.61 | 1 | 2025 |
Source payment records
|
|||||
| KENGREAL Normalized: kengreal |
Drug | Chiesi USA, Inc. | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| AURORA EV-ICD MRI SURESCAN Normalized: aurora ev icd mri surescan |
Device | Medtronic, Inc. | $15.23 | 2 | 2025 |
Source payment records
|
|||||
| Passeo-18 Normalized: passeo 18 |
Device | BIOTRONIK INC. | $12.17 | 2 | 2025 |
Source payment records
|
|||||
| Pulsar-18 T3 Normalized: pulsar 18 t3 |
Device | BIOTRONIK INC. | $12.17 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $6.57 | 1 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $5.61 | 1 | 2025 |
Source payment records
|
|||||
| BIOMONITOR Normalized: biomonitor |
Device | BIOTRONIK INC. | $2.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 699 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 57 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
57 | 21 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
699 | 225 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
123 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 704 | 322 |
| Entresto | Sacubitril/Valsartan | 699 | 225 |
| Furosemide | Furosemide | 561 | 247 |
| Metoprolol Tartrate | Metoprolol Tartrate | 556 | 232 |
| Gabapentin | Gabapentin | 436 | 172 |
| Atorvastatin Calcium | Atorvastatin Calcium | 426 | 177 |
| Eliquis | Apixaban | 348 | 124 |
| Losartan Potassium | Losartan Potassium | 334 | 132 |
| Carvedilol | Carvedilol | 239 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 222 | 97 |
| Clonidine Hcl | Clonidine Hcl | 203 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 93 |
| Lisinopril | Lisinopril | 193 | 91 |
| Xarelto | Rivaroxaban | 190 | 74 |
| Brilinta | Ticagrelor | 157 | 46 |
| Amiodarone Hcl | Amiodarone Hcl | 141 | 60 |
| Alprazolam | Alprazolam | 135 | 39 |
| Ozempic | Semaglutide | 123 | 43 |
| Nitroglycerin | Nitroglycerin | 113 | 64 |
| Sertraline Hcl | Sertraline Hcl | 106 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 101 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 41 |
| Metformin Hcl | Metformin Hcl | 93 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 35 |
| Celecoxib | Celecoxib | 86 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 38 |
| Omeprazole | Omeprazole | 83 | 36 |
| Ranolazine Er | Ranolazine | 81 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 77 | 53 |
| Nebivolol Hcl | Nebivolol Hcl | 75 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 30 |
| Meloxicam | Meloxicam | 69 | 30 |
| Labetalol Hcl | Labetalol Hcl | 61 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 29 |
| Verquvo | Vericiguat | 57 | 21 |
| Tramadol Hcl | Tramadol Hcl | 56 | 34 |
| Midodrine Hcl | Midodrine Hcl | 55 | 19 |
| Farxiga | Dapagliflozin Propanediol | 54 | 19 |
| Ibuprofen | Ibuprofen | 50 | 35 |
| Vascepa | Icosapent Ethyl | 49 | 20 |
| Atenolol | Atenolol | 48 | 19 |
| Simvastatin | Simvastatin | 48 | 19 |
| Digoxin | Digoxin | 47 | 16 |
| Ezetimibe | Ezetimibe | 46 | 20 |
| Clonidine | Clonidine | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 17 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 42 | 16 |
| Meclizine Hcl | Meclizine Hcl | 41 | 26 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Metolazone | Metolazone | 38 | 12 |
| Valsartan | Valsartan | 36 | 15 |
| Pregabalin | Pregabalin | 35 | 17 |
| Icosapent Ethyl | Icosapent Ethyl | 34 | 15 |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Azithromycin | Azithromycin | 33 | 30 |
| Diltiazem Hcl | Diltiazem Hcl | 32 | 14 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 32 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 19 |
| Allopurinol | Allopurinol | 29 | 14 |
| Linzess | Linaclotide | 28 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 11 |
| Torsemide | Torsemide | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | suppressed |
| Glipizide | Glipizide | 26 | 12 |
| Megestrol Acetate | Megestrol Acetate | 26 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 20 |
| Famotidine | Famotidine | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Lorazepam | Lorazepam | 19 | 11 |
| Spironolactone | Spironolactone | 19 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,598.80 · 49 records | Penumbra, Inc. | ABRE, AMVIA EDGE, AURORA EV-ICD MRI SURESCAN, Acticor 7 VR-T DX, BIOMONITOR, Barostim Neo System, COBALT DR MRI SURESCAN, COREVALVE EVOLUT R, ENDURANT IIS, ENTRESTO, FFRct, INSPIRE, Indigo System, KENGREAL, Kerendia, LEQVIO, LifeVest, PERCLOSE PROGLIDE, Passeo-18, Pulsar-18 T3, Rivacor 7 DR-T, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VENASEAL, VERQUVO, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Merck Sharp & Dohme LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error